InsiderSignal.AI

InsiderSignal.ai

IRON - Disc Medicine, Inc.

Insider Sale by Franchi Jean M. (CFO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Franchi Jean M., serving as CFO at Disc Medicine, Inc. (IRON), sold 6,657 shares at $69.23 per share, for a total transaction value of $460,834.00. Following this transaction, Franchi Jean M. now holds 64,333 shares of IRON.

This sale represents a 9.00% decrease in Franchi Jean M.'s stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, April 13, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, April 15, 2026, 2 days after the trade was made.

Disc Medicine, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Franchi Jean M.

CFO

Jean Franchi is an experienced Chief Financial Officer at Disc Medicine, Inc., a clinical-stage biopharmaceutical company focused on treatments for hematologic diseases[[1]](https://www.globenewswire.com/news-release/2024/02/07/2825134/0/en/Disc-Medicine-Strengthens-Leadership-Team-with-Appointment-of-Seasoned-Industry-Executive-Jean-Franchi-as-Chief-Financial-Officer-and-Promotion-of-Jonathan-Yu-to-Chief-Operating-Of.html). She brings over 30 years of finance leadership expertise across public and private biotechnology companies at all stages of development[[1]](https://www.globenewswire.com/news-release/2024/02/07/2825134/0/en/Disc-Medicine-Strengthens-Leadership-Team-with-Appointment-of-Seasoned-Industry-Executive-Jean-Franchi-as-Chief-Financial-Officer-and-Promotion-of-Jonathan-Yu-to-Chief-Operating-Of.html). Most recently, she served as CFO at Replimune, where she raised over $750 million across multiple financings and non-dilutive debt[[1]](https://www.globenewswire.com/news-release/2024/02/07/2825134/0/en/Disc-Medicine-Strengthens-Leadership-Team-with-Appointment-of-Seasoned-Industry-Executive-Jean-Franchi-as-Chief-Financial-Officer-and-Promotion-of-Jonathan-Yu-to-Chief-Operating-Of.html). Her prior roles include Chief Financial Officer positions at Merrimack Pharmaceuticals, Dimension Therapeutics (acquired by Ultragenyx), and Good Start Genetics[[1]](https://www.globenewswire.com/news-release/2024/02/07/2825134/0/en/Disc-Medicine-Strengthens-Leadership-Team-with-Appointment-of-Seasoned-Industry-Executive-Jean-Franchi-as-Chief-Financial-Officer-and-Promotion-of-Jonathan-Yu-to-Chief-Operating-Of.html). Franchi spent 16 years at Genzyme, where she advanced to Senior Vice President of Finance for all nine business units and then Senior Vice President of Corporate Finance, playing a key role in Genzyme's approximately $20.1 billion sale to Sanofi[[1]](https://www.globenewswire.com/news-release/2024/02/07/2825134/0/en/Disc-Medicine-Strengthens-Leadership-Team-with-Appointment-of-Seasoned-Industry-Executive-Jean-Franchi-as-Chief-Financial-Officer-and-Promotion-of-Jonathan-Yu-to-Chief-Operating-Of.html). She holds a Bachelor's degree in Business Administration from Hofstra University[[1]](https://www.globenewswire.com/news-release/2024/02/07/2825134/0/en/Disc-Medicine-Strengthens-Leadership-Team-with-Appointment-of-Seasoned-Industry-Executive-Jean-Franchi-as-Chief-Financial-Officer-and-Promotion-of-Jonathan-Yu-to-Chief-Operating-Of.html). Franchi joined Disc Medicine in February 2024, where she leads finance, investor relations, capital formation, and other functions[[1]](https://www.globenewswire.com/news-release/2024/02/07/2825134/0/en/Disc-Medicine-Strengthens-Leadership-Team-with-Appointment-of-Seasoned-Industry-Executive-Jean-Franchi-as-Chief-Financial-Officer-and-Promotion-of-Jonathan-Yu-to-Chief-Operating-Of.html). As of February 2026, she directly owns 82,499 shares of Disc Medicine common stock and holds options for an additional 25,500 shares[[3]](https://www.stocktitan.net/sec-filings/IRON/form-4-disc-medicine-inc-insider-trading-activity-3c9d74343455.html). Her appointment reflects Disc's transition into late-stage development and commercialization planning, leveraging her extensive experience scaling organizations focused on rare diseases[[1]](https://www.globenewswire.com/news-release/2024/02/07/2825134/0/en/Disc-Medicine-Strengthens-Leadership-Team-with-Appointment-of-Seasoned-Industry-Executive-Jean-Franchi-as-Chief-Financial-Officer-and-Promotion-of-Jonathan-Yu-to-Chief-Operating-Of.html).

View full insider profile →

Trade Price

$69.23

Quantity

6,657

Total Value

$460,834.00

Shares Owned

64,333

Trade Date

Monday, April 13, 2026

3 days ago

SEC Filing Date

Wednesday, April 15, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Disc Medicine, Inc.

Company Overview

No company information available
View news mentioning IRON

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5667074

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime